Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | F3 | P13726 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142012 | 0.86 | PDK1 (0.43) | ADORA1CYP3A4LMNATSHRALDH1A1 | |
| SCHEMBL4152825 | 0.86 | L3MBTL1 (0.38) | ADORA1TSHRALDH1A1ABCB1 | |
| SCHEMBL4152600 | 0.86 | PDE4B (0.40) | TSHRALDH1A1MAPK1 | |
| SCHEMBL4135614 | 0.85 | PDK1 (0.45) | LMNATSHRALDH1A1ABCB1 | |
| SCHEMBL4139976 | 0.85 | PDK1 (0.35) | CYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL4145213 | 0.85 | ADORA1 (0.42) | ADORA1DRD1DRD2F3SIGMAR1 | |
| SCHEMBL4140663 | 0.84 | HTR2C (0.42) | ALDH1A1 | |
| SCHEMBL4135531 | 0.84 | S1PR1 (0.42) | LMNATSHRALDH1A1 | |
| SCHEMBL4145313 | 0.84 | CRHBP (0.44) | SIGMAR1CYP3A4ALDH1A1 | |
| SCHEMBL4139873 | 0.83 | NAAA (0.46) | CYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | ADORA1 331/4885DRD1 251/4885DRD2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.